Invasive Candidiasis in Critical Care

Launched by UNIVERSITY HOSPITAL OSTRAVA · Jun 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to quickly identify and diagnose invasive candidiasis, a serious fungal infection that can occur in critically ill patients, especially those in intensive care units (ICUs). The researchers are using a special test called "T2Candida" along with monitoring certain markers in the body that indicate infection. By doing this, they hope to improve how accurately doctors can diagnose this condition, which could lead to better treatment and lower costs for antifungal medications.

To be eligible for this trial, patients must be critically ill and have signs of infection, such as a high fever above 38°C, and must be experiencing new onset sepsis (a severe infection that spreads in the body). They should also have evidence of Candida fungus from multiple non-sterile sites, like skin or other body areas. Participants will be closely monitored, and their test results will help determine the presence of the infection more quickly. It's important to note that patients who are already receiving antifungal treatment or who do not agree to participate will not be included in the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • critically ill patients
• • new onset sepsis
• • rise in body temperature \>38°C according to The Third Consensus Definitions for Sepsis and Septic Shock
• • colonization with Candida spp. from more than 1 non-sterile site
• • body temperature \>38 °C despite 5 days of broad-spectrum antibiotic therapy with the presence of at least 1 of the following risk factors: abdominal surgery, secondary peritonitis, pancreatitis, central venous catheter (CVC) insertion, total parenteral nutrition (CPV), dialysis, steroid therapy, immunosuppressive therapy, or liver transplantation
• • microbiological test results will be reviewed and categorized based on whether Candida sp. is isolated from at least 2 non-sterile sites (±3 days) and whether there is an alternative microbiological diagnosis.
• Exclusion Criteria:
• • not signing the informed consent with participation in the study
• • administration of antifungal therapy prior to collection of the biological material required for the study